Pioneering allergy research

Under­standing allergy

ALK has an unrivalled understanding of allergens and how they affect the human body, as well as the link between allergy and respiratory diseases such as asthma.



  • Post date
    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
  • Post date
    Nine-month interim report (Q3) 2018
  • Post date
    Correction: Release date of nine-month interim report (Q3) 2018 and audio cast
  • Post date
    Release date of nine-month interim report (Q3) 2018 and audio cast
  • Post date
    UK authority extends use of specific batches of Jext® as adrenaline pen shortage continues
  • Post date
    ALK submits registration application for tree SLIT-tablet in Europe
  • Post date
    Six-month interim report (Q2) 2018
  • Post date
    Release date of six-month interim report (Q2) 2018 and audio cast
  • Post date
    Three-month interim report (Q1) 2018
ALK launches growth strategy
Transformational strategy to redefine ALK's position in the global allergy market and stimulate a new era of growth for the company.
Growth strategy: Establish and succeed in North America
North America is the world's largest allergy market, with over 50 million allergy sufferers, and it offers ALK the greatest medium-term growth potential. For example, there are around 10 million AIT-eligible allergy sufferers in the USA alone, just one-third of whom actually receive AIT today.
Growth strategy: Complete the tablet portfolio for all relevant ages
ALK is committed to offering a full portfolio of tablets for all relevant ages, covering the five most common global respiratory allergies.
Growth strategy: Patient engagement systems and adjacent business
ALK will establish a new commercial consumer care division to drive digital patient engagement with the ultimate aim of creating new value from ALK's expanded allergy presence.

ALK in brief

ALK at a glance
ALK is a research-driven, global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. We are the foremost innovators in allergy immunotherapy – a unique treatment which reduces allergic symptoms and treats the cause of the allergy.
Global presence
ALK employs around 2,300 employees worldwide and has affiliates, production facilities and distributors around the globe. Today, around 1.5 million people worldwide use our products.
ALK's pipeline
Our development programme covers the four most important outdoor allergens in Europe, the USA and Japan (grass, birch and related trees, ragweed and Japanese cedar) and the most important indoor allergen in the world (house dust mites).
ALK's history
ALK has been at the forefront of allergy treatment for almost a century. Our story can be traced back to a small laboratory in Copenhagen, Denmark, in 1923.